Lithera to Present at Three Upcoming Conferences
SAN DIEGO, Calif. – October 5, 2010 – Lithera, Inc. today announced that it will
present key clinical data and progress updates on the development of LIPO-102, its novel
injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for
selective, non-ablative fat reduction. Lithera will present at the following three
– 2010 Joint Annual Meeting of the American Society for Dermatologic Surgery/
American Society of Cosmetic Dermatology and Aesthetic Surgery on Friday,
October 22, 2010, at 2:19 PM at the Hyatt Regency Chicago on the Riverwalk
Dr. Adam M. Rotunda (Assistant Clinical Professor of Dermatology, David Geffen
School of Medicine, UCLA) will deliver a presentation entitled “Evaluation of LIPO-102
(Salmeterol Xinafoate (SX) + Fluticasone Propionate (FP) for Injection) for the
Reduction of Abdominal Subcutaneous Fat”. Clinical data will be presented showing that
LIPO-102 produces significant reductions in abdominal circumference and volume.
– Oppenheimer 21st Annual Healthcare Conference on Tuesday, November 2, 2010,
at 11:25 AM in the Louis XVI Room at The Waldorf-Astoria in New York City
Dr. John D. Dobak (Chief Executive Officer, Lithera, Inc.) will present a progress update
on the development of LIPO-102 as well as late-breaking clinical study results.
– Windhover’s Therapeutic Area Partnerships on Wednesday, November 3, 2010, at
2:30 PM at the Westin Copley Place in Boston
LIPO-102 was selected as one of the Top 10 Projects to Watch in our Hot Space by
Windhover Information and the publishers of In Vivo and Startup. Dr. John D. Dobak
will present a progress update on the development of LIPO-102 as well as late-breaking
About LIPO-102
LIPO-102 is being developed as a first-in-class injectable drug product designed to
produce local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA-
registered drugs approved for use in other indications, LIPO-102 targets and stimulates
natural fat tissue metabolism to achieve non-ablative, non-surgical fat tissue reduction in
specific locations. LIPO-102 is currently under development for the treatment of
symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-
related eye disease (the thyroid condition is also known as Graves’ Disease) and the
About Lithera
Lithera is a clinical stage company developing pharmaceutical and biomedical products
addressing both medical and lifestyle indications in ophthalmology and aesthetic
medicine. Our lead product candidate (LIPO-102) is a novel injectable pharmaceutical
product designed to produce local, selective fat tissue reduction (pharmaceutical
lipoplasty). Founded in 2007, the Company has assembled an exceptional team of senior
executives, employees and advisors and has been financed by top-tier venture capital
firms. For more information on Lithera, Inc., please visit
Lithera, LIPO-102 and the Lithera logo are trademarks or registered trademarks of
Lithera, Inc. Other names and brands may be claimed as the property of others.
Please take notice that the attached Magistrate Judge’s Reporthas been filed with the Clerk of the U. S. District Court. In accordance with 28 U.S.C. §636(b)(1), you have 14 daysafter being served with the attached report to file writtenobjections to the proposed findings of fact, conclusions of law,and recommendations set forth therein. Failure to file writtenobjections to the proposed find
Glossary ACP Acepromazine: Mild oral or injected sedative. Comealong Correctional rope halter for impressing Adequan Intramuscular injectable aid to joint wear and ‘Follow Me’ lesson. See War bridle. tear. Oral equivalent is chondroitin sulphate. Seek Crooked knees Blanket term for knee deformity. See text. Cut Castrate, geld, make a gelding. Back up, or down State of mu
